These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30610229)

  • 1. Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy.
    Strianese D; Rossi F
    Eye (Lond); 2019 Feb; 33(2):191-199. PubMed ID: 30610229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye Disease.
    Strianese D
    Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S56-S59. PubMed ID: 29923966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
    Kossler AL; Douglas R; Dosiou C
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.
    Smith TJ
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S13-S26. PubMed ID: 36346686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future Projections in Thyroid Eye Disease.
    Barbesino G; Salvi M; Freitag SK
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.
    Ayabe R; Rootman DB; Hwang CJ; Ben-Artzi A; Goldberg R
    Ophthalmic Plast Reconstr Surg; 2014; 30(5):415-9. PubMed ID: 24978425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the management of thyroid eye diseases: An overview.
    Kumari R; Chandra Saha B
    Int Ophthalmol; 2018 Oct; 38(5):2247-2255. PubMed ID: 28822031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
    Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Era in the Treatment of Thyroid Eye Disease.
    Patel A; Yang H; Douglas RS
    Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biological treatment options for Graves' ophthalmopathy].
    El Fassi D; Nielsen CH; Hegedüs L
    Ugeskr Laeger; 2008 Jun; 170(24):2128-30. PubMed ID: 18565294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
    Janssen JAMJL; Smith TJ
    Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease.
    Strianese D
    Curr Opin Ophthalmol; 2017 Sep; 28(5):505-513. PubMed ID: 28700384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease.
    Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN
    Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425
    [No Abstract]   [Full Text] [Related]  

  • 15. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach.
    Sipkova Z; Insull EA; David J; Turner HE; Keren S; Norris JH
    Clin Endocrinol (Oxf); 2018 Dec; 89(6):834-839. PubMed ID: 30103255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
    Wall JR; Lahooti H
    Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
    Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
    Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Graves' ophthalmopathy.
    Salvi M
    Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):409-14. PubMed ID: 25105999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical treatment in thyroid eye disease in 2020.
    Khong JJ; McNab A
    Br J Ophthalmol; 2021 Mar; 105(3):299-305. PubMed ID: 32447327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.